BioCatalyst

Masupirdine 50 mg, Masupirdine 100 mg — catalyst calendar

1 verified catalyst event(s) referencing Masupirdine 50 mg, Masupirdine 100 mg, each linked to its official source. Verified as of 2026-09-20.

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-12 (month)
in 2mo
ESTIMATED
 READOUT
Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type
Phase 3 · Agitation, Alzheimer's Type Dementia
 Suven Life Sciences Limited Masupirdine 50 mg, Masupirdine 100 mg ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.